1. Scrip
  2. >>Business
  3. >>Earnings

Lilly’s CVOT Success With Trulicity Causes Bullish Outlook For Diabetes Franchise

 
• By Joseph Haas

Lilly reported strong sales growth for many of its recently launched products, but news of the potentially differentiating REWIND cardiovascular outcomes trial data dominated the pharma’s third quarter earnings call.

David Ricks
Lilly CEO David Ricks

Eli Lilly & Co. reported that a host of products launched since 2014 made up 35% of its third quarter revenue and drove 14% volume growth in the company’s pharmaceutical business, but the success of Trulicity (dulaglutide) in a cardiovascular outcomes trial (CVOT) overshadowed the company's earnings report on Nov. 6.

Lilly revealed a day earlier that the GLP-1 agonist – now its top-selling drug – demonstrated superiority compared to placebo in the reduction of major adverse cardiovascular events (MACE) in the REWIND CVOT study in a broad range of type 2 diabetes patients

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Takeda Plans US Investment But Sees Little Impact From Tariffs

 
• By Alaric DeArment

The Japanese drug maker is on track for three pivotal Phase III readouts and two regulatory submissions in 2025.

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma

 
• By Jessica Merrill and Joseph Haas

Neurocrine, Madrigal and Vanda updated investors on new drug launches, while Cytokinetics talked to investors about an FDA extension for aficamten.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

Sarepta Slammed By Double Blow: Elevidys Sales Miss, Prasad’s CBER Appointment

 
• By Mandy Jackson

Sarepta’s stock price was battered after Vinay Prasad was appointed to lead the US FDA’s CBER, then the company’s shares were bruised when Q1 Elevidys sales came in below consensus.

More from Business